Erschienen in:
01.07.2014 | Original Article—Liver, Pancreas, and Biliary Tract
Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C
verfasst von:
Yasuhiro Asahina, Kaoru Tsuchiya, Takashi Nishimura, Masaru Muraoka, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Takanori Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Mina Nakagawa, Sei Kakinuma, Mamoru Watanabe, Namiki Izumi
Erschienen in:
Journal of Gastroenterology
|
Ausgabe 7/2014
Einloggen, um Zugang zu erhalten
Abstract
Background
We aimed to clarify the association between single nucleotide polymorphism (SNP) located near interleukin 28B and hepatocellular carcinoma (HCC).
Methods
A cohort comprising 792 patients treated with interferon for chronic hepatitis C was investigated. SNPs at rs8099917 and rs12979860 were determined. Cumulative incidence and HCC risk were analyzed by Kaplan–Meier and Cox proportional hazard analyses for a mean follow-up period of 4.9 years. Fibrosis progression rate (FPR) was determined in these patients with a known time of infection (n = 294).
Results
Cumulative HCC incidence was significantly higher in rs8099917 nonTT (minor homozygote or heterozygote) patients than in rs8099917 TT (major homozygote) patients (20.8 vs. 10.5 % over 10 years, logrank test, p = 0.002). This difference was notable in patients infected with genotype 1 and those treated with pegylated interferon and ribavirin. Among nonSVRs, interferon had a limited effect in suppressing alanine aminotransferase (ALT) and/or α-fetoprotein (AFP) levels in nonTT patients. The suppression of these values after interferon therapy was associated with a lower incidence of HCC. FPR were similar in TT and nonTT patients.
Conclusions
rs8099917 nonTT is related to higher HCC development in patients with HCV genotype 1 and those treated with pegylated interferon and ribavirin. Higher HCC incidence observed in nonTT patients partly results from the limited suppression of ALT and/or AFP by interferon in these patients.